Cancer Immunotherapy News and Research

RSS

Exploring the potential of MSCs in cancer therapy

A new review was published in Oncotarget's Volume 15 on November 22, 2024, entitled "Mesenchymal stem cells – the secret agents of cancer immunotherapy: Promises, challenges, and surprising twists."

4 Dec 2024

New study explores heart risks of cancer immunotherapy

A cancer therapy that prompts the body's immune defenses against viruses and bacteria to attack tumors can make patients more vulnerable to heart attack and stroke.

2 Dec 2024

Targeting intracellular checkpoints to enhance NK cell immunotherapy

Natural killer (NK) cells are pivotal in the innate immune response against cancer and viral infections, with their presence in tumors correlating to better patient outcomes in various cancers.

27 Nov 2024

MR1 molecule and vitamin B6 could unlock new paths for cancer immunotherapy

Effective immunity hinges on the ability to sense infection and cellular transformation. In humans, there is a specialized molecule on the surface of cells termed MR1.

27 Nov 2024

AI-designed drug ISM5939 granted IND clearance for cancer clinical trials

Insilico Medicine ("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced that it has received IND clearance from FDA for ISM5939, a potential best-in-class oral small molecule inhibitor targeting ENPP1 for the treatment of solid tumors.

22 Nov 2024

New CAR T-cell therapy shows promise against aggressive HER2+ breast cancer

One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast cancer with a poorer prognosis. Investigators of the Vall d'Hebron Institute of Oncology's (VHIO) Growth Factors Group, in collaboration with researchers of the Cancer Research Program of Hospital del Mar Research Institute (HMRI), Barcelona, have developed novel chimeric antigen receptor (CAR) T-cell therapy that can produce a potent antitumor response against p95HER2-expressing cells.

19 Nov 2024

Gut microbiome found to play key role in chronic disease progression

The gut microbiome, an ecosystem of trillions of microorganisms in the human digestive tract, has been increasingly linked to chronic diseases.

15 Nov 2024

Duke-NUS team develops test to monitor engineered T cells in cancer treatment

A novel test developed by Duke-NUS researchers enables real-time monitoring of T cells that have been engineered to fight cancer, after re-introduction into the body of a cancer patient.

15 Nov 2024

Customizable biological sensors activate cancer immunotherapy only in tumor environments

Most cancer treatments – from chemotherapies to engineered immune cells – have a host of side effects, in large part because they affect healthy cells in the body at the same time as targeting tumor cells.

15 Nov 2024

Nomic® and Parker Institute for Cancer Immunotherapy (PICI) launch large-scale protein profiling to investigate immunotherapy responses in RADIOHEAD study

Nomic Bio and PICI collaborate to quantify protein biomarkers in cancer immunotherapy, enhancing understanding of patient responses and treatment resistance.

From Nomic 12 Nov 2024

Researchers uncover metabolic blockade that impedes cancer treatment response

The immune system is a major target for cancer treatments. Immune checkpoint inhibitors and CAR-T cell therapy can dramatically improve outcomes for many cancers. But for about 70% of patients, these therapies don't work.

8 Nov 2024

Virtual screening yields small molecules to enhance cancer immunotherapy

The process of identifying promising small molecule drug candidates that target cancer checkpoints may become faster and smarter through virtual screening, according to Weill Cornell Medicine researchers.

7 Nov 2024

Rice bioengineers uncover why IL-12 immunotherapy loses effectiveness

A team of Rice University bioengineers has developed a mathematical model that clarifies why interleukin-12 (IL-12) ⎯ a potent immune-boosting protein that holds promise for cancer treatment ⎯ loses effectiveness over time when used as an immunotherapeutic.

6 Nov 2024

Researchers uncover immune mechanism behind myocarditis from cancer immunotherapy

Some patients being treated with immune checkpoint inhibitors, a type of cancer immunotherapy, develop a dangerous form of heart inflammation called myocarditis.

6 Nov 2024

Researchers awarded Synergy Grant to target tumor vessels and boost immunotherapy

Targeting and customizing blood vessels in tumors to increase T cell infiltration and maintain their function may represent the next breakthrough in cancer therapy.

5 Nov 2024

Combination therapy shows promising results in treating stage 3 melanoma

Pre-surgery treatment with the novel drug vidutolimod and the PD-1 checkpoint inhibitor nivolumab led to tumor control in 55% of patients with stage 3 cutaneous melanoma, according to the results of a single-arm phase 2 clinical trial led by the University of Pittsburgh, UPMC Hillman Cancer Center and the National Cancer Institute (NCI).

1 Nov 2024

New therapeutic target overcomes ovarian cancer immunotherapy resistance

Researchers at the Icahn School of Medicine at Mount Sinai have discovered a way that ovarian cancer tumors manipulate their environment to resist immunotherapy and identified a drug target that could overcome that resistance.

1 Nov 2024

Researchers develop new approach to predict immunotherapy response in breast cancer patients

Using computational tools, researchers from the Johns Hopkins Kimmel Cancer Center and the Johns Hopkins University School of Medicine have developed a method to assess which patients with metastatic triple-negative breast cancer could benefit from immunotherapy.

29 Oct 2024

Discovery of stem-like CD4 T cells offers new hope for cancer immunotherapy

Researchers at Winship Cancer Institute of Emory University have identified a novel type of immune cell, called the stem-like CD4 T cell, that plays a pivotal role in anti-tumor immunity.

26 Oct 2024

New CAR T cells offer controlled treatment for solid tumors

Ludwig Cancer Research scientists have devised new types of chimeric antigen-receptor (CAR) T cells - a type of cancer immunotherapy - that can be switched on to varying degrees of intensity and then switched off on demand with existing drugs.

21 Oct 2024